Baird upgrades Northrop Grumman stock rating on strong results

Baird upgraded Northrop Grumman to Outperform from Neutral and raised its price target to $675 from $552 after Q3 2026 results beat expectations for revenue and adjusted EPS; adjusted EPS was $7.89 versus $7.18 expected, while revenue of $11.12B was in line with forecasts. The company raised full-year earnings guidance, reported stronger cash flow and a record backlog exceeding twice annual revenue, and outlined multi-year growth targets through 2028. Baird said a large B-21 charge appears less likely in coming quarters.

Analysis

The upgrade is most useful as a signal that near-term execution risk may be easing—not proof that backlog will convert into attractive returns. The key equity driver is whether order visibility turns into sustained segment growth and cash generation without adverse cost-to-complete revisions. A backlog-to-revenue ratio alone says little about delivery timing, funding, cancellation risk, or program economics.

The less-consensus risk is that reduced expectations for another large B-21 charge become embedded before independently verifiable cost evidence arrives. Any unfavorable estimate-at-completion update could quickly undo the improved confidence; unchanged assumptions are not the same as lower risk. Over 1–3 months, watch reported cash conversion, segment-level growth, and program cost disclosures. Over 6–18 months, appropriations and contract funding determine how much of the backlog becomes revenue. Better execution could support a relative premium to defense peers; weaker conversion would expose the stock to multiple compression after an upgrade-led rerating.

Key Decisions for Investors

• Consider a modest long NOC versus a broad U.S. defense ETF on post-upgrade weakness, rather than chasing strength. The relative thesis is company-specific execution; keep exposure small until cash conversion and program cost trends confirm it. Reassess if guidance is cut or cost estimates worsen.
• Use the next earnings release as the main 1–3 month checkpoint: verify segment growth, operating cash flow conversion, and any cost-to-complete updates, especially on B-21. Treat the analyst view that a large charge is less likely as a hypothesis, not a company commitment.
• Falsifiers: a material unfavorable program-cost revision, weaker-than-guided cash generation, or delayed/at-risk funding that prevents backlog conversion. Conversely, sustained growth and cash conversion without adverse cost updates would support holding the relative long into the 6–18 month horizon.